Program
liposomal doxorubicin
Also written as “PLD”, “Doxorubicin Hydrochloride Liposome Injection” and “Pegylated liposomal doxorubicin”.
Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Multiple Myeloma · Carcinoma, Ovarian Epithelial · Endometrial Neoplasms, led by 16 companies.
Drug pageLiposomal doxorubicin: every studyMany companies study it; this page follows only the 33 they lead. All 210 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 90 open or running | phase 3since Apr 29, 2004 | Apr 29, 2004 | none ahead |
| Merckits history only | 60 open or running | phase 4since Jan 21, 2008 | Dec 15, 2005 | none ahead |
| CSPC Pharmaceutical Group | 20 open or running | phase 2since Dec 11, 2017 | Dec 11, 2017 | none ahead |
| Imunonits history only | 20 open or running | phase 2since Nov 1, 2011 | Jun 5, 2003 | none ahead |
| Oncotherapeuticsits history only | 20 open or running | phase 2since Aug 26, 2008 | Aug 26, 2008 | none ahead |
| TTY Biopharmits history only | 20 open or running | phase 2since Aug 31, 2010 | Aug 31, 2010 | none ahead |
| Ayana Pharmaits history only | 10 open or running | phase 1since Sep 17, 2018 | Sep 17, 2018 | none ahead |
| Azaya Therapeuticsits history only | 10 open or running | phase 1since Oct 19, 2012 | Oct 19, 2012 | none ahead |
| Baxter Healthcareits history only | 10 open or running | phase 1since Sep 29, 2022 | Sep 29, 2022 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 1since Sep 22, 2014 | Sep 22, 2014 | none ahead |
| Luye Pharma Groupits history only | 10 open or running | phase 1since Oct 18, 2023 | Oct 18, 2023 | none ahead |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Mar 13, 2006 | Mar 13, 2006 | none ahead |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceuticalits history only | 10 open or running | phase 1since Aug 31, 2014 | Aug 31, 2014 | none ahead |
| Shenzhen Kangzhe Pharmaceuticalits history only | 10 open or running | phase 1since Feb 10, 2022 | Feb 10, 2022 | none ahead |
| Takedaits history only | 10 open or running | phase 2since Jan 28, 2008 | Jan 28, 2008 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 2since Jul 8, 2008 | Jul 8, 2008 | none ahead |
Also a collaborator on its studies: Eisai, Novotech (Australia) Pty, Lambda Therapeutic Research, MDS Pharma Services, Essex Pharma, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA, Ortho Biotech, Tibotec Pharmaceutical, Sequus Pharmaceuticals and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSPC Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2017First study: phase 2 study in Poorly Differentiated Thyroid CarcinomaFirst studyNCT03387943 · 30 enrolled · China
- Jul 2, 2020No phase study in BioequivalenceNCT04460820 · 32 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04460820Bioequivalence · China | – | Completed | Dec 23, 2019 | 32 |
| NCT03387943Poorly Differentiated Thyroid Carcinoma · China | 2 | UNKNOWN | Dec 31, 2018 | 30 |
How it is read
Names in the registry
- “PLD”, 4 entries
- “Doxorubicin Hydrochloride Liposome Injection”, 4 entries
- “Pegylated liposomal doxorubicin”, 3 entries
- “Pegylated Liposomal Doxorubicin (PLD)”, 2 entries
- “liposomal doxorubicin”, 2 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 16 studies
- Breast Neoplasms, 13 studies
- Multiple Myeloma, 5 studies
- Carcinoma, Ovarian Epithelial, 3 studies
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.